Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1614 Riluzole <1 mg/mL 46 mg/mL 46 mg/mL
S6001 pomaglumetad (LY404039) <1 mg/mL 1 mg/mL <1 mg/mL
S1245 Latrepirdine 2HCl <1 mg/mL 24 mg/mL 13 mg/mL
S2251 (-)-Huperzine A (HupA) <1 mg/mL 0.66 mg/mL <1 mg/mL
S2861 CTEP (RO4956371) <1 mg/mL 78 mg/mL 10 mg/mL
S5137 O-Phospho-L-serine 37 mg/mL <1 mg/mL -1 mg/mL
S4774 Xanthurenic Acid -1 mg/mL 7 mg/mL -1 mg/mL
S2690 ADX-47273 <1 mg/mL 74 mg/mL 30 mg/mL
S2795 VU 0357121 <1 mg/mL 61 mg/mL 21 mg/mL
S2809 MPEP <1 mg/mL 39 mg/mL 39 mg/mL
S8035 VU 0364439 <1 mg/mL 85 mg/mL <1 mg/mL
S1893 D-glutamine 9 mg/mL <1 mg/mL <1 mg/mL
S2860 IEM 1754 2HBr 82 mg/mL 82 mg/mL <1 mg/mL
S3070 Piracetam 72 mg/mL 72 mg/mL <1 mg/mL
S2862 VU 0364770 <1 mg/mL 47 mg/mL 47 mg/mL
S2892 VU 0361737 <1 mg/mL 53 mg/mL <1 mg/mL
S4716 Evans Blue 100 mg/mL 100 mg/mL <1 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations


Riluzole is a glutamate release inhibitor with neuroprotective, anticonvulsant, anxiolytic and anesthetic qualities.


pomaglumetad (LY404039)

LY404039 is a potent agonist of recombinant human mGlu2/mGlu3 receptors with Ki of 149 nM/92 nM, shows >100-fold selectivity over ionotropic glutamate receptors, glutamate transporters, and other receptors. Phase 3.


Latrepirdine 2HCl

Latrepirdine is an orally active,and neuroactive antagonist of multiple drug targets, including histamine receptors, GluR, and 5-HT receptors, used as an antihistamine drug.


(-)-Huperzine A (HupA)

(-)-Huperzine A is a potent, highly specific and reversible inhibitor of acetylcholinesterase (AChE) with Ki of 7 nM, exhibiting 200-fold more selectivity for G4 AChE over G1 AChE. Also acts as an NMDA receptor antagonist. Phase 4.


CTEP (RO4956371)

CTEP (RO4956371) is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, shows >1000-fold selectivity over other mGlu receptors.



O-Phospho-L-serine, a molecule that mimics the phosphatidylserine head group and partially blocks microglial phagocytosis of apoptotic cells, is a specific group III metabotropic glutamate receptor (mGluR) agonist.


Xanthurenic Acid

Xanthurenic acid, a molecule arising from tryptophan metabolism by transamination of 3-hydroxykynurenine, activates mGlu2/3 Metabotropic glutamate receptors (mGlu2 and mGlu3).



ADX47273 is a potent and specific mGlu5 positive allosteric modulator(PAM) with EC50 of 0.17 μM, showing no activity at other mGlu subtypes.


VU 0357121

VU0357121 is a novel positive allosteric modulator (PAM) of mGlu5 with EC50 of 33 nM, is inactive or very weakly antagonizing at other mGlu receptor subtypes.



MPEP is a selective mGlu5 receptor antagonist with IC50 of 36 nM, exhibits no appreciable activity at mGlu1b/2/3/4a/7b/8a/6 receptors.


VU 0364439

VU 0364439 is a mGlu4 positive allosteric modulator (PAM), with EC50 of 19.8 nM.



D-glutamine is a D type stereoisomer of glutamine which is one of the 20 amino acids encoded by the standard genetic code.


IEM 1754 2HBr

IEM 1754 2HBr is a selective AMPA/kainate receptor blockers for GluR1 and GluR3 with IC50 of 6 μM.



Piracetam is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders.


VU 0364770

VU 0364770 is a positive allosteric modulator(PAM) of mGlu4 with EC50 of 1.1 μM, exhibits insignificant activity at 68 other receptors, including other mGlu subtypes.


VU 0361737

VU 0361737 is a selective positive allosteric modulator (PAM) for mGlu4 receptor with EC50 of 240 nM and 110 nM at human and rat receptors, respectively, displays weak activity at mGlu5 and mGlu8 receptors, is inactive at mGlu1, mGlu2, mGlu3, mGlu6 and mGlu7 receptors, can penetrate into CNS.


Evans Blue

Evans Blue is a potent inhibitor of the uptake of L-glutamate into synaptic vesicles, also an AMPA/kainate receptor antagonist.

Tags: Glutamate receptor activation | Glutamate receptor signaling | mGlur signaling | mGlur pathway | Glutamate receptor cancer | mGlur5 signaling | mGlur5 pathway | mGlur signaling pathway | mGlur5 drugs | Glutamate receptor inhibitor review